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Abstract
Metformin is used as an anti-diabetic drug. Metformin ameliorates insulin resistance by improving insulin sensitivity in liver
and skeletal muscle. Reduced mitochondrial content has been reported in type 2 diabetic muscles and it may contribute to
decreased insulin sensitivity characteristic for diabetic muscles. The molecular mechanism behind the effect of metformin is
not fully clarified but inhibition of complex I in the mitochondria and also activation of the 59AMP activated protein kinase
(AMPK) has been reported in muscle. Furthermore, both AMPK activation and metformin treatment have been associated
with stimulation of mitochondrial function and biogenesis. However, a causal relationship in skeletal muscle has not been
investigated. We hypothesized that potential effects of in vivo metformin treatment on mitochondrial function and protein
expressions in skeletal muscle are dependent upon AMPK signaling. We investigated this by two weeks of oral metformin
treatment of muscle specific kinase dead a2 (KD) AMPK mice and wild type (WT) littermates. We measured mitochondrial
respiration and protein activity and expressions of key enzymes involved in mitochondrial carbohydrate and fat metabolism
and oxidative phosphorylation. Mitochondrial respiration, HAD and CS activity, PDH and complex I-V and cytochrome c
protein expression were all reduced in AMPK KD compared to WT tibialis anterior muscles. Surprisingly, metformin
treatment only enhanced respiration in AMPK KD mice and thereby rescued the respiration defect compared to the WT
mice. Metformin did not influence protein activities or expressions in either WT or AMPK KD mice. We conclude that two
weeks of in vivo metformin treatment enhances mitochondrial respiration in the mitochondrial deficient AMPK KD but not
WT mice. The improvement seems to be unrelated to AMPK, and does not involve changes in key mitochondrial proteins.
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Introduction
Metformin is worldwide the most prevalently used drug to treat
type 2 diabetes and have been utilized in the clinic for more than
five decades to improve insulin sensitivity [1,2]. Type 2 diabetes
mellitus is associated with decreased insulin sensitivity in liver and
skeletal muscle. It has been reported that diabetic muscles have
reduced mitochondrial content as well as protein expressions and
activities and this may contribute to skeletal muscle insulin
resistance [3–5]. However, several other studies have not
confirmed these findings [6–10]. The molecular mechanisms
behind the effects of metformin are not fully clarified. Although
inhibition of complex I in the mitochondrial electron transport
chain (ETC) in cells, isolated mitochondria and muscle homog-
enate has been reported [11–15] consensus is not reached [16,17].
In addition, metformin-induced activation of the 59-AMP activat-
ed protein kinase (AMPK) has been shown in rodent muscles [18–
20], and in human skeletal muscles from patients with type 2
diabetes [21,22]. AMPK is a heterotrimeric kinase with a catalytic
a subunit and regulatory b and c subunits. AMPK activity is
enhanced when the AMP:ATP and/or ADP:ATP ratio within the
cell increases. Upon activation AMPK inhibits ATP consuming
pathways and enhances ATP producing pathways and thereby
acts as a cellular fuel gauge [23–25]. Stimulation of AMPK by
metformin is not via direct interaction [18,26,27]. Instead
activation has been suggested to be linked to the inhibition of
mitochondrial complex I, that may lead to a disturbance in cell
energy balance and thus AMPK activation [13,27,28], although
other studies suggest that the metformin-induced activation is not
dependent of such changes in the energy status of the cell [26,29].
Numerous studies using transgenic models and pharmacological
AMPK activation have documented a role for AMPK in
regulating mitochondrial function and biogenesis [30–34]. On
the other hand it is sparse with reports on the potential effects of
metformin treatment on mitochondrial function besides the above
mentioned studies in regard to complex I inhibition. Some studies
suggest that metformin also affects mitochondrial oxidative stress
by decreasing ROS production [17,35,36] and interestingly, an in
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vitro study with endothelial cells has shown AMPK dependent
metformin-induced promotion of mitochondrial biogenesis [37].
In muscles, stimulation of PGC-1a, a key regulator of mitochon-
drial biogenesis [38], has been reported both in vitro and in vivo
after long term metformin treatment [20,39,40] together with
increased activities and protein expressions of mitochondrial
marker enzymes [20,40].
Even though metformin treatment and AMPK signaling both
have been associated to mitochondrial regulation no study has to
our knowledge investigated a possible causal relationship in
skeletal muscle. Thus, we hypothesized that potential effects in
skeletal muscle of metformin treatment in vivo on mitochondrial
function and protein expressions are dependent upon AMPK
signaling. Therefore, we genetically investigated the role of AMPK
for metformin to stimulate mitochondrial function and biogenesis




Experiments were approved by the Danish Animal Experimen-
tal inspectorate and complied with the European Convention for
protection of vertebra animals used for scientific purposes. The
mice used in these experiments were muscle specific kinase dead
a2 (KD) AMPK mice that have been described previously [41].
The female mice were 22–30 weeks old littermates on a C57BL/6
background. Wild type (WT) littermates were used as controls for
the genetic model.
Treatment
All animals were kept on a 12 h/12 h light/dark cycle with
unlimited access to standard rodent chow food and water. Cages
were provided with bedding, shelter and bit stick.
WT and KD mice were divided into two groups; one treated
with metformin and the other given saline. Metformin
(2*150 mg*kg21*day21) and saline solutions were administered
by gavage twice daily in the morning and afternoon for two weeks.
The last dosage of metformin/saline was given the afternoon
before the experimental day. On the experimental day mice were
anesthetized by intraperitoneal injection of pentobarbital
(0.1 mg*g body wt21). TA muscles were isolated from both legs.
One portion of TA was put in a relaxing buffer (content is
described below) and used for high resolution respirometry, while
the rest and the whole other TA was frozen in liquid nitrogen and
stored at 280uC for later analysis.
Preparation of permeabilized skeletal muscle fibers for
high resolution respirometry
The TA muscle tissue was subjected to mechanical dissection
with sharp forceps in relaxing buffer on ice. The relaxing buffer
contained 2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 20 mM
imidazole, 20 mM taurine, 6.56 mM MgCl2, 5.77 mM ATP,
15 mM phosphocreatine, 0.5 mM dithiothreitol, and 50 mM K-
MES, pH 7.1. Fiber bundles were permeabilized by gentle
agitation for 30 min at 4uC in the relaxing solution, supplemented
with 50 mg/ml saponin. Fiber bundles were then washed in ice-
cold respiration medium (content described below) 2610 minutes
at 4uC during gentle agitation.
High-resolution respirometry
Respiration was measured at 37uC in a high resolution
respirometer (Oroboros, Oxygraph; Innsbruck, Austria). The
respiration medium consisted of 110 mM sucrose, 60 mM K-
lactobionate, 0.5 mM EGTA, 1 g/l BSA essentially fatty acid free,
3 mM MgCl2, 20 mM taurine, 10 mM KH2PO4, 20 mM K-
HEPES, pH 7.1. The software DatLab (Oroboros) was used for data
analysis. The use of permeabilized fibers provides the possibility to
study mitochondria ‘‘in situ’’ in the cell, and very small muscle
samples (2–4 mg) are needed to study mitochondrial respiration.
Mitochondrial respiration protocol: In order to avoid any
potential oxygen diffusion limitation all experiments were
conducted after hyper-oxygenation (450 nmol O2/ml). Substrate
and inhibitor were added consecutively, one protocol was
employed, made in duplicate. State 2 respiration was assessed
with malate (2 mM) a complex I substrate. State 3 respiration was
reached with ADP (5 mM) and subsequently glutamate (10 mM)
another complex I substrate. This was followed by succinate
(10 mM) a complex II substrate, resulting in parallel electron input
to complex I and II. Cytochrome c (10 mM) was added to control
for outer mitochondrial membrane integrity. Finally rotenone
(0.5 mM) was added to inhibit complex I. Malate and glutamate
are providing NADH for complex I and succinate is providing
FADH for complex II.
Muscle lysate preparation used for Western blot analyzes
and homogenates used for Citrate Synthase (CS) and 3-
Hydroxyacyl-CoA Dehydrogenase activity (HAD) activity
For extraction of proteins the whole muscle were homogenized
in ice cold buffer (10% glycerol, 20 mM sodium pyrophosphate,
150 mM sodium chloride, 50 mM HEPES, 1% NP-40, 20 mM b-
glycerophosphate, 10 mM sodium fluoride, 2 mM PMSF, 1 mM
EDTA, 1 mM EGTA, 10 mg/ml aprotinin, 10 mg/ml leupeptin,
2 mM Sodium orthovanadate, 3 mM benzamidine, pH 7.5) by a
tissue lyser for 2*1 min at 30 Hz (Tissue Lyser II, Qiagen Retch,
Germany). Muscle homogenates were rotated end over end at 4uC
for 1 hour, after which they were centrifuged for 20 min at
15.000 g. The supernatants were harvested as the muscle lysate
and stored at 280uC. Total lysate protein content was determined
by the bicinchoninic acid method (Pierce Biotechnology, Inc., IL,
USA). Muscles used for HAD and CS activity were homogenized
in ice cold buffer (0.3 M potassium phosphate pH=7.7, 0.05%
BSA) by a tissue lyser for 2*1 min at 30 Hz (Tissue Lyser II,
Qiagen Retch, Germany). HAD and CS activity were measured
on the homogenate as described below.
SDS page and Western blot analyzes
Lysate proteins were separated by SDS-PAGE on self cast Tris-
HCl (7–12%) gels and by semidry blotting transferred to a PVDF
membrane (Immobilon Transfer Membranes; Millipore, Bagsværd,
Denmark). The membrane was blocked in a washing buffer (10 mM
Tris-base, 150 mM NaCl and 0.25% Tween 20) containing low fat
milk protein milk or BSA solution and afterwards probed with
primary antibodies and appropriate secondary antibodies (see
below). Protein bands were visualized using a Kodak Image Station
(2000 MM, Kodak, N.Y., USA) after probing with enhanced
chemiluminescence (ECL, Millipore, Mass, USA). Bands were
quantified using Kodak 1D 3.6 software (Kodak, N.Y., USA).
Antibodies used for detection of specific phosphorylation
sites and protein expressions. Mitochondria complex I
protein expression: Complex I, Molecular Probes, Invitrogen
(#A31857); CA, USA. Mitochondria complex II protein expres-
sion: Complex II, Molecular Probes, Invitrogen (#A11142); CA,
USA. Mitochondria complex III protein expression: Complex III,
Molecular Probes, Invitrogen (#A21362); CA, USA. Mitochon-
dria complex IV protein expression: Anti-Oxphos Complex IV
Subunit I Monoclonal Antibody, Invitrogen (#459600), CA, USA.
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Mitochondria Complex V: F1-ATPase, Santa Cruz Biotechnology
(#sc-16689); CA, USA. Cyt C protein expression: Anti-Cyto-
chrome C monoclonal antibody: BD Biosciences(#556433); NJ,
USA. Pyruvate Dehydrogenase (PDH) subunit E1a (PDH-E1a)
protein expression and PDH-E1a site 1 (Ser293) and Site2
(Ser300) phosphorylations were determined as described previ-
ously [42]. Acetyl-CoA carboxylase (ACC) phosphorylation at
Ser221: anti-phospho-Acetyl CoA Carboxylase (Ser79), Upstate
Biotechnology, MA, USA (#07-303); anti AMPK a1 and a2
protein expressions: anti AMPK a1 and a2 specific antibodies
raised in sheep as previously described [43] was kindly donated by
Hardie DG, University of Dundee, Scotland, UK.
Secondary HRP-conjugated antibodies used were from Dako
(Glostrup, Denmark).
Citrate Synthase (CS) and 3-Hydroxyacyl-CoA
Dehydrogenase activity (HAD) activity
CS and HAD activity was measured in a reaction coupled to
conversion of NAD to NADH by spectrophotometric determination
of NADH changes at 340 nm at 37uC, pH 7.0, in muscle
homogenates, using an automatic analyzer (Hitachi automatic
analyzer 912; Boehringer Mannheim, Ingelheim, Germany). CS
activity was measured with acetyl-CoA and oxaloacetate as substrate
and HAD measured with acetoacetyl-CoA as substrate [44]
Statistics
Differences between groups were evaluated by Two-Way
ANOVA or Students t-test. Significant main effects or interactions
were further analyzed by Student-Newman-Keuls method as post
hoc test. Differences between groups were considered statistically
significant when P,0.05. All data are expressed as means 6
S.E.M.
Results
Decreased state 3 mitochondrial respiration in AMPK KD
compared to WT muscle is normalized after metformin
treatment
Mitochondrial respiration was significantly decreased in TA
muscles of saline treated AMPK KD compared to WT mice when
Figure 1. Figure 1A+B: Mitochondrial respiratory capacity in TA muscles from WT and KD mice treated with metformin or saline for two weeks. A:
Mitochondrial respiration (O2 flux) related to milligram muscle. B: Mitochondrial respiration (O2 flux) related to milligram muscle and expressed
relative to mitochondrial content (CS activity). Dark grey bars shows results in TA muscles from saline treated WT mice. Light grey bars shows results
in TA muscles from saline treated KD mice. Dark grey bars with slashes shows results in TA muscles from metformin treated WT mice. Light grey bars
with slashes shows results in TA muscles from metformin treated KD mice. {: Indicate significant difference between genotype within intervention
(P,0.05). #: Indicate significant difference between interventions in AMPK KD mice (P,0.05). {: Indicate significant interaction between genotype
and intervention (P,0.05). *: Indicate significant main effect of genotype (P,0.05). n = 11–14. Values are means 6 S.E.M. Figure 1C: Substrate control
ratio (SCR) is calculated as state 3 respiration with complex I and II linked substrates divided by state 3 respiration with complex I linked substrates.
White bars shows results in TA muscles from saline treated mice. Black bars shows results in TA muscles from metformin treated mice. n = 11–14.
Values are means 6 S.E.M.
doi:10.1371/journal.pone.0053533.g001
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measured per milligram of muscle (Fig. 1A). There was no
difference in state 2 respiration (Fig. 1A, Malate) but state 3
respiration was reduced by ,20% (P,0.05) with electron flux
through complex I (Fig. 1A, Malate, Glutmate and ADP) and by
,20% (P,0.01) with electron flux through complex I+II (Fig. 1A,
Malate, Glutmate, ADP and Succinate) in saline treated AMPK
KD compared to WT mice. Rotenone was added to inhibit
complex I, but this inhibition did not affect the above described
differences, i.e. ,20% reduced respiration in AMPK KD
compared to WT muscle (Fig. 1A, Rotenone). Furthermore, we
calculated the substrate control ratio (SCR) for succinate (state 3
respiration with complex I and II linked substrates and state 3
respiration with complex I linked substrates). There was no
significant effect of genotype or treatment in SCR, but a tendency
was seen (P= 0.062) for the treatment in the KD mice, indicating
that the difference in respiration could be explained by a different
complex II linked respiration (Fig. 1C)
Two weeks of oral metformin treatment did not influence
mitochondrial respiration in WT muscles but stimulated state 3
respiration in KD muscles through complex II (Fig. 1A, P,0.05),
supported by the tendency found in SCR in the KD mice after
metformin treatment. This implies that the defect in electron flux
through complex II in KD muscles were rescued compared to WT
muscles (Fig. 1A, P,0.05). These findings indicate a defect in KD
mice mitochondrial complex II or downstream of complex II in
the ETC that is rescued upon metformin treatment. Mitochondrial
membrane integrity was controlled by addition of cytochrome c
(results not shown).
When mitochondria O2 flux rates were expressed relative to
mitochondrial content, i.e. CS activity, there were no longer
significant differences in state 3 respiration with electron flux
through complex I (Fig. 1B, Malate, Glutamate and ADP) and II
(Fig. 1B, Malate, Glutamate, ADP and Succinate). This indicates
that the observed difference in mitochondria respiration between
WT and KD muscles in saline treated mice (Fig. 1A) is due to
decreased mitochondrial content in KD muscles. There was a
main effect of genotype in state 2 respiration after normalization to
CS activity (Fig. 1B, Malate).
However, the different effect of metformin treatment in WT
and KD muscles persisted after adjusting respiration to mitochon-
drial content (Fig. 1B, Succinate). I.e. that metformin-induced
stimulation of mitochondrial respiration with ,30% in KD mice
probably was caused by enhancement of mitochondrial function
and not mitochondrial content.
Reduced protein expressions of mitochondria respiration
chain complex I-V and cytochrome C in AMPK KD
compared to WT muscles but no effect of metformin
treatment
To elucidate whether the observations on mitochondrial
respiration in regard to the role of AMPK and metformin
treatment are reflected in the different protein complexes of the
mitochondrial ETC, we choose to measure protein expression on a
subset of proteins representing complex I–V and cytochrome c in
the ETC (Fig. 2A–2F and Fig. 3). AMPK KD mice had generally
decreased protein expression levels of these complexes and
cytochrome c in the range of 10–25% (Fig. 2A–2F, P,0.05).
Figure 2. Protein expressions of Complex I–V and Cytochrome C of the mitochondria electron transport chain in TA muscles from
WT and KD mice treated with metformin or saline for two weeks. White and black bars shows results from saline treated and metformin
treated mice respectively. A: Complex I protein expression. B: Comp lex II protein expression. C: Complex III protein expression. D: Cytochrome C
protein expression. E: Complex IV protein expression. F: Complex V protein expression. *: Indicates significant difference between genotype (P,0.05).
(*): P = 0.059. N= 12–17. Values are S.E.M.
doi:10.1371/journal.pone.0053533.g002
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Metformin treatment did not change protein expressions in either
WT or KD muscles.
Reduced PDH expression in AMPK KD compared to WT
muscles but no effect of metformin treatment on PDH
expression or phosphorylation
The pyruvate dehydrogenase complex (PDH) enzyme catalyzes
conversion of pyruvate to acetyl-CoA and is a key regulator of
carbohydrate-derived substrate into the tricarboxylic acid cycle
(TCA cycle). The PDH protein expression was decreased ,15%
in muscles from AMPK KD mice compared to WT muscles, but
the expression was not regulated by metformin treatment in either
of the genotypes (Fig. 4A) Phosphorylation at site 1 and site 2 on
the PDH enzyme is believed to reduce its activity [45] but none of
these sites were significantly affected by genotype or metformin
treatment (Fig. 4B–E and Fig. 3).
Reduced HAD and CS activity in AMPK KD compared to
WT muscles but no effect of metformin treatment
HAD and CS activity was measured as key enzymes in the b-
oxidation and TCA cycle respectively. HAD activity was repressed
about 15% in AMPK KD muscles but there was no effect of
metformin treatment in either of the genotypes (Fig. 5A). Similarly
CS activity was repressed about 10% in AMPK KD muscles and
not influenced by metformin treatment (Fig. 5B).
Evaluation of remaining endogenous AMPK a subunit
expression and activity in muscles from AMPK-KD mice
The AMPK-KD mice used in the present study are derived
from over-expressing a kinase dead Lysine45 – Arginine mutant of
the 59AMP activated protein kinase (AMPK) a2 protein, driven by
the heart and skeletal muscle specific creatine kinase promoter
[41]. As shown in figure 6A, a Western blot of AMPK a2 in
muscles from WT and AMPK KD mice, there is no detectable
band at the expected molecular weight of the endogenous a2
protein in the AMPK KD muscles. Due to a myc-tag, the
transgenic a2 protein can be detected as a slightly heavier and
stronger band compared to the WT a2 protein which is detected at
,63 kDa. Furthermore over-expression of the kinase dead a2
protein results in a ,50% reduction of a1 protein content as
shown in figure 6B. As an indirect measure of both a1 and a2
associated activity we evaluated Ser212 phosphorylation of ACC,
an AMPK substrate (Fig. 3+6C). Based on the ACC phosphor-
ylation total AMPK activity in muscles from AMPK KD mice are
reduced to ,10% compared with muscles from wild type mice.
Furthermore, there was no significant effect of the chronic
metformin treatment on ACC phosphorylation in wild type or
KD muscles. Notice that the last dose of metformin/saline was
given the afternoon before muscles were isolated from the
anesthetized mice. Consequently, the graphic illustration repre-
sents the chronic and not the acute effect of metformin on ACC
phosphorylation.
Discussion
The aim of the present study was to investigate potential effects
of two weeks of in vivo metformin treatment on mitochondrial
function as well as activity and expression of mitochondrial
proteins. We hypothesized that these assumed metformin effects in
skeletal muscle would be dependent upon AMPK signaling.
To our knowledge we are the first to elucidate the consequence
of genetically induced AMPK down regulation on mitochondrial
respiration after metformin treatment in skeletal muscle. We
observed decreased mitochondrial respiration related to electron
flux through mitochondrial complex I and II in TA muscles from
AMPK KD mice. Metformin treatment did not affect mitochon-
drial respiration or mitochondrial protein content and activity in
WT muscles. However, metformin stimulated mitochondrial
respiration in KD muscles. Thus, mitochondrial respiration via
electron flux through complex II and/or downstream of complex
II in the ETC was enhanced in KD muscles. Electron flux through
complex I was unaffected by metformin. Since neither of the
mitochondrial marker enzymes representing the ETC, TCA cycle
and b-oxidation were changed by the metformin treatment we
assume that the stimulating effect of complex II or downstream
should be ascribed to increased function, rather than expression, of
one or more of these ETC complexes. This assumption is
supported by persistence of the enhanced respiration through
complex II or downstream in ETC, when mitochondrial
respiration was expressed relative to mitochondrial content (CS
activity).
The lack of a metformin-induced effect on respiration and
mitochondrial enzymes in WT mice is in accordance with a recent
study by Kane et al. [17] in rat muscle, although they measured on
the combined effect of chronic (4 weeks) and acute (4 hours) effect
of metformin treatment. In contrast, another study in rats by Suwa
et al. [20] showed increased activities of both CS and HAD as well
Figure 3. Representative Western blots of Complex I–V,
Cytochrome C, Pyruvate Dehydrogenase (PDH) subunit E1a
protein, PDH site1 and PDH site2 phosphorylation and
ACCSer211 phosphorylation.
doi:10.1371/journal.pone.0053533.g003
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as increased expression of cytochrome c protein, after 2 weeks
metformin treatment. The reason(s) for these discrepancies is not
obvious, but could be related to the applied metformin dose. The
study by Kane et al. used similar to the present study
,300 mg kg21 daily while the dosage was doubled in the Suwa
et al. study to above 600 mg kg21 daily. It is not possible to
deduce whether the lack of an effect on these mitochondrial
enzymes is due to the lower dose used. In the present study,
metformin treatment is equivalent to most other in vivo rodent
studies using 200–300 mg kg21 daily [17,46–49]. Although this
dose is ,7–10 times higher than recommended dose used in
humans [50,51] the literature reports comparable blood levels of
metformin in humans and mice with the denoted treatment
models [46,50]. Therefore the dose used in the present and the
study by Kane et al. probably elicits metformin levels comparable
to a clinical situation. CS activity was measured in the
predominantly glycolytic TA muscles in the present study whereas
in the study by Kane et al. measurements were performed in the
Figure 4. PDH site 1 and 2 phosphorylation and protein expression in TA muscles from WT and KD mice treated with metformin or
saline for two weeks.White and black bars shows results from saline treated and metformin treated mice respectively. A: PDH protein expession. B:
PDH site 1 phosphorylation. C: PDH site 1 phosphorylation related to PDH protein expression. D: PDH site 2 phosphorylation. E: PDH site 1
phosphorylation related to PDH protein expression. *: Indicates significant difference between genotype (P,0.05). N = 12–17. Values are S.E.M.
doi:10.1371/journal.pone.0053533.g004
Figure 5. HAD and CS activity in TA muscles from WT and KD mice treated with metformin or saline for two weeks. White and black
bars shows results from saline treated and metformin treated mice respectively. A: HAD activity. B: CS activity. *: Indicates significant difference
between genotype (P,0.05), N = 12–17. Values are S.E.M.
doi:10.1371/journal.pone.0053533.g005
Metformin AMPK and Mitochondria in Skeletal Muscle
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e53533
red oxidative part of gastrocnemious. Suwa et al. reported
increased activity in both the red oxidative and white glycolytic
part of gastrocnemious and also in soleus. These observations do
not support a possible fibre type specific effect and a species
specific difference is also doubtful since both Kane et al. and Suwa
et al. studied rat muscles. Kane et al. used few animals (n = 4)
compared to Suwa et al. (n = 8) and the present study (n= 12–17)
which reduces the statistical power in the Kane study and thereby
the risk of not detecting a potential difference. On the other hand,
our study supporting the lack of an effect in the Kane et al. study is
not biased by low statistical power. So the most obvious reason for
the lack of a metformin effect is probably the lower metformin
dose used by Kane et al. and us. This perspective is supported by
newly published observations in muscles from patients with type 2
diabetes [7,16]. Larsen et al. [16] found that metformin treatment
of these patients did not affect complex I respiration and stated
that clinical metformin treatment does not affect mitochondrial
function in human skeletal muscle.
Unexpectedly we did see a stimulating effect of mitochondrial
respiration in AMPK KD but not in WT muscles. In our view
there is no obvious explanation for this finding, but we have some
suggestions. If metformin, as shown in cell studies [11–14,52], also
inhibits complex I in these in vivo settings, there could be a
potential redirection of substrate flux feeding into complex II and
downstream in the ETC. In analogy to a physical exercise training
regime this could induce an increased stress on mitochondrial
ETC proteins downstream of complex I and a consequence could
be adaptations to the stress leading to increased mitochondrial
function which is also a common effect of exercise training [53,54].
The reason why this only occurs in KD muscles could be a general
reduction in mitochondrial protein expressions and activities.
Meaning that a given stress stimuli on the muscle cell, e.g.
metformin inhibition of complex I, is relatively higher the lower
the initial mitochondrial content. On the other hand there are
some observations in the study by Kane et al. [17] that could
question these suggestions. First, in contrast to the in vitro cell
studies, Kane et al. did not observe any inhibition of electron flux
trough complex I four hours after in vivo metformin treatment with
320 mg kg21. Consequently making it unlikely that we see an
inhibition in the present study, where we divided the daily
metformin dose into 2 feedings of 150 mg kg21. On the other
hand, it is possible that metformin-induced cellular stress in the
more glycolytic TA muscle is amplified compared to the oxidative
red gastrocnemious in the Kane study. Second, Kane et al. also
missed a metformin effect in obese rats that like our KD mice had
decreased mitochondrial capacity, based on CS activity. Accord-
ingly, the argument of increased metformin-induced cell stress due
to decreased mitochondrial capacity is not fully in line with the
observations in the Kane et al. study, but again it is possible that
susceptibility to mitochondrial reductions is different in glycolytic
vs. oxidative muscles. An alternative hypothesis could be that
AMPK, which as mentioned above function as a cellular energy
gauge, somehow make the cell able to better cope with potential
mitochondrial stress, induced by metformin. Thus, it is possible
that the AMPK signaling pathway by an unknown mechanism
counter regulates the metformin-induced inhibition of the
oxidative metabolism, i.e. the ETC complex I, such that stress-
induced adaptation of the ETC is absent. Observations of
increased disturbances in muscle cell energy balance, indicative
of greater cell stress, when genetic AMPK hampered mice are
stressed by in vivo exercise support these thoughts i.e. greater
metformin-induced cellular stress in AMPK KD muscles vs. WT
muscles [55–58]. Additionally, such a connection was recently
demonstrated in AMPK a1a2 double KO hepatocytes showing
greater ATP decrease than wild type cells upon metformin
incubation [52,59].
Like in the AMPK defective mice, reduced mitochondrial
content have been reported in skeletal muscles from patients with
type 2 diabetes [3,60]. Consequently, if diabetic muscles also have
decreased AMPK expression and activity it could be suggested,
based upon the speculations above, that metformin treatment of
these patients enhances mitochondrial function. Although one
study reports attenuated exercise induced AMPK activation in
obese type 2 diabetic patients [61], and another study suggest that
Figure 6. Protein expression of AMPKa subunits and ACC
Ser221 phosphorylation. A: Representative Western blot of AMPK a2
in AMPK WT and KD muscles. The absence of a detectable band at the
expected molecular weight of ,63 kDa in KD mice muscles indicates a
strongly reduced endogenous a2 protein expression. Instead the
slightly heavier band in KD muscles is detection of the myc-tag
transgenic a2 protein. B: a1 protein expression in WT and AMPK KD
muscles. *: Indicates significant difference between genotype, P,0.001,
n = 10. Values are means6 S.E.M. C: ACC Ser221 phosporyaltion in AMPK
WT and KD muscle lysates (TA) from chronic saline (white bars) and
metformin (black bars) treated mice. *: Indicates significant difference
between genotype, P,0.001, n = 11–14. Values are means 6 S.E.M.
doi:10.1371/journal.pone.0053533.g006
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obesity has been shown to be inversely related to AMPK protein
expressions in non diabetic humans [62], the majority of studies
have shown no effect of type 2 diabetes on AMPK subunit protein
expressions or basal and exercise induced activity [63–66]. Hence,
it may be difficult to transfer the results from the present study of
metformin-induced enhancement of mitochondrial function into
clinical conditions, but further investigations on this topic in
diabetic patients seem highly relevant.
Since a role for AMPK in mitochondrial function of skeletal
muscle first time was elucidated for more than a decade ago by
Winder et al. [30] numerous studies have expanded the knowledge
in this field. Use of pharmacological AMPK activators [33,40,67–
70], genetic models [32,34,55,56,58,71–73] and combination of
these [31,33,74] have substantiated AMPK as an important
mitochondriogenic part. The kinase is involved both in mainte-
nance of basal mitochondrial function and enhancement of
mitochondrial enzymes and mitochondrial biogenesis upon
increased AMPK activation. Hence, the decreased basal activities
of CS and HAD, as key enzymes in the TCA cycle and b-
oxidation, in the present study is a common observation reported
in the AMPK KD strain [73,75] and in comparable AMPK
genetic model [31,34,55]. Also the decreased PDH protein
expression, as a key regulator of carbohydrate metabolism, has
been reported earlier in muscle of the AMPK whole body a2
knockout mice [55] and the muscle specific AMPK KD mice
strain [75]. We recently reported decreased complex II and V
protein expressions in the AMPK KD mice [75] but the present
study is the first describing the expression profile of proteins
representing all ETC complexes in the AMPK a subunit
genetically manipulated model. Decreased expressions of these
complexes have also been reported in AMPK b1b2 muscle
knockout mice [34] and in LKB1 KO mice muscles, i.e. in muscles
lacking the primary upstream AMPK kinase [56,72]. Furthermore
Lee et al. have looked at the individual activities of these
complexes in muscles from a similar AMKP KD mouse strain as in
the present study [57]. Their findings are partly in accordance
with ours as they found decreased comlex I and V activities but no
difference in the other complexes. The genotype difference on
complex I and V persists when they are normalized to CS activity,
in contrast to our finding with mitochondrial respiration through
complex I and II. So Lee al. deduced that the genotype differences
were not due to decreased mitochondrial content. This difference
between the present study and Lee et al. could be due to
methodological conditions and/or muscle type differences, since
Lee et al. assayed the activities on homogenates of gastrocnemious
while we measured respiration on whole muscle pieces from TA.
Conversely, increased protein expression of complex I–IV has
been shown in an alternative AMPK genetic model with an
AMPK activating mutant of the regulatory c3 subunit [32]. In that
study mitochondrial respiration was also measured and in
accordance with findings in the present study there were no
genotype differences with electron flux through complex I and II
when normalized to mitochondrial content. So, based on these
studies it is a rather consistent finding that the AMKP system is
important for regulation of oxidative phosphorylation via the ETC
complexes. Although it is not fully resolved whether the genotype
effect primarily is due to protein expression differences or
functional conditions of the individual complex.
A possible limitation in our study is that not all endogenous
AMPK activity is eliminated in the used AMPK transgenic model.
Although we did not measure a1 or a2 associated activities directly
in the present study based on the ACC Ser221 phosphorylation, an
AMPK substrate, AMPK activity is reduced to ,10% in AMPK
KD muscles compared to WT muscle tissue. Our observations are
in line with previous studies, using the AMPK KD mice, reporting
a1 and a2 activities to be reduced with,90% [76–78] and,50%
[76,77], respectively, although a1 associated activity in one study
was only moderately reduced (,10%) [78]. Thus if AMPK is the
only ACC Ser221 kinase then the ACC phosphorylation indicates
that KD mice, in accordance with the previous studies, may have a
small remaining AMPK activity. However, in our opinion the
remaining AMPK activity in the AMPK KD mice does not affect
our interpretation of the results and our suggestions.
We conclude that two weeks in vivo metformin treatment do
not affect mitochondrial function or proteins in WT mice when
applying a dose assumed to elicit plasma concentrations
comparable to the clinical use of metformin. In contrast, in
the mitochondrial deficient model of a2-AMPK KD mice,
mitochondrial respiration is enhanced by metformin treat-
ment. This metformin effect cannot be explained by regulation
of mitochondrial key enzymes representing carbohydrate and
fat metabolism or oxidative phosphorylation.
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